Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating) major shareholder Milton C. Ault III purchased 16,100 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The stock was bought at an average cost of $0.89 per share, with a total value of $14,329.00. Following the acquisition, the insider now owns 9,836,667 shares in the company, valued at approximately $8,754,633.63. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of ALZN opened at $0.94 on Friday. Alzamend Neuro, Inc. has a 52-week low of $0.80 and a 52-week high of $33.55. The firm’s fifty day moving average is $1.04 and its two-hundred day moving average is $1.49.
Alzamend Neuro (NASDAQ:ALZN – Get Rating) last announced its earnings results on Tuesday, March 15th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). As a group, analysts forecast that Alzamend Neuro, Inc. will post -0.12 earnings per share for the current fiscal year.
Alzamend Neuro Company Profile (Get Rating)
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.
- Get a free copy of the StockNews.com research report on Alzamend Neuro (ALZN)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.